Distress
BioHarvest Sciences (BHST) auditor flags going concern doubt for 2025
BioHarvest Sciences Inc. (Nasdaq: BHST) said in its 2025 annual report, dated March 31, 2026, that its auditor found substantial doubt about its ability to continue as a going concern.

BioHarvest Sciences Inc. (Nasdaq: BHST) filed audited financial statements for 2025 in an annual report on Form 40-F dated March 31, 2026. The auditor, Ziv Haft of BDO Member Firm in Tel-Aviv, wrote that there is substantial doubt about the company's ability to continue as a going concern. The firm has served as the company's auditor since 2019. The statements are in U.S. dollars, in thousands, and show a 2025 net loss of $11,135 thousand.
Why is this important: A going concern doubt is the auditor's warning that the company may not be able to keep operating without more capital. The company reported cash and cash equivalents of $23,025 thousand at December 31, 2025, against negative operating cash flow of $7,226 thousand for the year. Holders now depend on the terms of whatever financing the company arranges next.
Zaki Rakib, the chairman of the board, and Ilan Sobel, the chief executive officer, approved the statements on March 31, 2026. In our view, a board that signs accounts with a going concern paragraph has to be judged on the funding plan it gives holders, and the filing offers a list of possible sources rather than a dated plan. Management says its existing cash should cover core needs for at least twelve months, assuming the deferral of certain non-essential capital expenditures. That claim sits against the auditor's doubt in the same filing.
The numbers behind the doubt
Revenue for 2025 was $34,508 thousand, and the accumulated deficit reached $107,553 thousand at year end. Current assets were $30,500 thousand against current liabilities of $7,684 thousand at December 31, 2025. Cash and cash equivalents rose from $2,390 thousand a year earlier to $23,025 thousand. Total shareholders' equity was $25,448 thousand at year end, against $1,330 thousand a year earlier.
The auditor's report refers to the going concern note, Note 1B, in the financial statements. The statements were approved on March 31, 2026. The management's discussion says the company has a history of operating losses and has not yet achieved sustained cash-flow profitability. Net cash used in operating activities was $6,684 thousand in 2024, against $7,226 thousand in 2025.
The management's discussion lists the sources the company may use to raise capital: equity or equity-linked securities, debt financing, strategic collaborations, licensing arrangements or other financing transactions. The discussion names no specific transaction and no closing date for any of them.
The Botanical Synthesis program and VINIA
The company describes its Botanical Synthesis Platform Technology as a way to grow active ingredients from fruits and plants in bioreactors at industrial scale, without growing the plant itself. Its first product entry is VINIA, a red grape powder made from red grape cells grown in the company's bioreactor facility. The management's discussion calls VINIA a polyphenol and anti-oxidant superfruit product.
The business description centers on two units: a products business that covers nutraceuticals, and a contract development and manufacturing business. The management's discussion says VINIA is the company's first product entry into the nutraceutical market.
What management says about funding
Management believes existing cash and cash equivalents, together with expected cash flows from operations, will be sufficient to fund core operating requirements for at least the next twelve months, assuming the deferral of certain non-essential capital expenditures and the execution of management's operating plan. The company is listed on the Nasdaq Capital Market and says it has previously demonstrated access to the capital markets. It also says there can be no assurance that additional financing will be available on acceptable terms, or at all.
The 2025 operating cash outflow was $7,226 thousand, and the year-end cash balance was $23,025 thousand. The auditor's paragraph and management's twelve-month statement of coverage are both in the same filing. Holders will need the next financing to tell which one proves right.
Investor Chat
Loading posts…
aibio